about
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaWill Listening to Music Make it Easier to Take a Visual Field Test?Investigation of Genetic Disease Marker Associated With Korean Glaucoma PatientsTransient visual field impairment after cold provocation in glaucoma patients with Flammer syndromeAssociation of the Myocilin Gene Polymorphism With Primary Open Angle GlaucomaEvaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) ParticipantsSignificant Association and Increased Risk of Primary Open Angle Glaucoma with Rs991967 Gene Polymorphism in North Eastern Iranian PatientsSubstances of Interest That Support Glaucoma TherapySafety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionEfficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular HypertensionStructure Function Correlation in Primary Open Angle GlaucomaComparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract SurgeryComparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic EyesThe Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration DeviceAn Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and MoreBlood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAGAqueSys XEN 45 Glaucoma Implant in Refractory GlaucomaSafety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular HypertensionBimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular HypertensionComparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle GlaucomaAssessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed CombinationTranscorneal Electrical Stimulation Therapy for Retinal DiseaseDose, Effects and Characteristics of PilocarpineHow Does Your Genetic Make-up (Profile) Influence Your Glaucoma?Posterior Cornea in Primary Open Angle GlaucomaThe Effects of an Antioxidant Formulation on Ocular Blood FlowComparison of Silicone and Porous Plate Ahmed Glaucoma ValvesMulticentric Observational Study on Quality of Life in GlaucomaDoes the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?The Efficacy of Selective Laser TrabeculoplastyResults of Ocular Compression and Suture Release in Trabeculectomy and Combined SurgeryFollowing Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle GlaucomaAutoimmune Dysregulation in Pigmentary GlaucomaAfrican Descent and Glaucoma Evaluation StudyDiagnostic Innovations in Glaucoma StudyCorneal Versus Conjunctival Delivery Using a Delivery DevicePigment Dispersion Syndrome With and Without GlaucomaStudy of TRAVATAN in Subjects With Iris Pigmentation Changes
P921
Q54816706-01F2E92B-F934-4121-847C-E70B2569A6CCQ54816765-42BE9FEF-B784-4C10-BC62-1C35E30B086AQ54816800-11E599BF-A015-410D-9C51-E1868BCBE0B1Q54816801-A3E6F1DC-5F69-4C41-B31E-DD5313AB3148Q54816802-92EA56A0-7837-4A61-B61C-EAC45367DEDAQ54816816-338E9737-A99C-4AB6-9B6A-9E42375594D6Q54816820-7AF06D4E-FB30-4804-BCCE-90C3ED34EEE1Q54816846-7F090B29-748B-4A50-A4AB-D676D15FB8C8Q54816852-70133C08-6DB2-4C1A-8036-0C4ABB0036A4Q54816871-0293E974-0F79-4530-9B98-66D79223C4A8Q54816872-9E7AFB3B-9BB7-4409-8560-041E3B8ACC60Q54816892-9916FD6A-5817-4948-9F5F-C4CF59BDEE6CQ54816896-007E47F5-1A2D-4EC6-9A05-D6B17A11CE36Q54816897-5935EDC9-FA4C-4A91-AD71-5BD2F1E55124Q54816900-1C214D2B-21BC-411E-8740-EB05086DA981Q54816913-6CB5EB44-FEAA-4D29-8C52-F1730AE6D11DQ54816916-B03BC92C-8767-4D93-AAED-0D67C3AA8F35Q54816964-4E15EC0F-EDCB-4BB5-9B5A-FEEC36CC7DE4Q54816980-57A9E752-52B9-4941-A086-F4D580D87C84Q54816987-95D32AEB-66AA-4879-94DA-7065C6E83F4AQ54852453-ADB07D56-2A3A-4C1A-8B96-57ECC422BDF7Q54852464-F83D68DE-0DAB-45B2-96C4-0280E033EC51Q54852483-D8DF7861-35F7-448B-99A8-8B1BE19A8EBEQ54852490-150A9C44-CF2B-4EAC-A129-F93E27BABC71Q54852491-FEAB4C22-6BBE-42EB-A1EB-91C56FBA9AC5Q54852492-A6C4F3B9-5562-489C-9F76-488E83260877Q54852551-6D43A339-F66F-40D7-A6D5-F7E23BDB4EF1Q54852557-0D137E17-695C-4F52-86DB-B9E74D63E75DQ54852558-00E8C082-88D7-4479-8271-203097844A77Q54852559-08249AA2-4890-4902-85BE-308A90E662F6Q54852574-B0C0D2E0-CBF6-4032-99F7-DF254D151022Q54852576-FDD0EEC6-A799-4FC8-9C9D-C8497E8F732BQ54852580-2303E037-F5D2-4365-A3FA-4A90187E212CQ54852581-87DD414A-941E-4A8D-99F9-0B9B0CB204BBQ54852582-7C29ED43-31E0-4B44-8C43-05620E2DF869Q54852583-D68F9AF2-8FB7-4778-845B-C70CBF7FE012Q54852588-FCF498D1-474A-4923-8335-5E568F3EF1D5Q54852589-DDDAECB9-2912-4657-A8CE-72FB80D1BDE2Q54852591-2064C585-DB8F-4CA8-9AF7-2377DB9EE7E2Q54852592-AE2F6862-8B50-4300-8E11-F27B1D531688
P5166
Q63829420-316D0A7A-DA9D-4A82-B84C-3AE81E5FCF3BQ63838752-538FC4A0-400C-49BF-95EF-414C4952D0D8Q63839512-EED4CFAB-6591-4413-AB48-8089088A5FECQ64059189-A5592CF7-3087-49FF-B588-D21894111146Q64082034-29700FC7-3AB6-4CA8-99D2-5EE36C5941D9Q64189205-B2E28FAD-AF20-4842-91C7-7AC178AA587DQ64240872-55104559-1FA0-42FF-8064-A77D55B11028Q64256610-5F7883A8-AC5F-4060-939D-930FF9C6B734Q64335795-62C42F53-B1DE-4233-BB86-8BDE20FBC5DCQ64348392-5690CDD7-2D4C-4016-80F8-7E598E44ADE2Q64349510-CB5AAE04-C6CE-4A98-9682-00A4E2A04B3AQ64349970-B40EFCED-FFA9-49C4-8163-6B2CFBC3CD28Q64350127-03410B2A-26D9-4028-8C1E-BF822571C9C7Q64350637-BEA3AD5A-AF3B-4A39-9F5D-46B928858318Q64352606-56325675-06A5-4471-9E04-B6164F5CA614Q64352766-16CF76C6-97A7-4AAE-9F20-1E52BC3661FCQ64397352-C2CD89E1-E9EA-4EA6-BE05-FB4CEA068068Q64606814-DA8352EC-26FF-4CC0-9EDC-DA3F975B1DFFQ64623051-299366A9-1BBA-4146-8B7F-5D129038D2D0Q64636558-52F90EA0-3280-4F32-AFFB-068D1764DE1AQ64638929-D61A37E7-3251-4A9D-9478-050EEE1C2569Q64645980-858F5E42-C500-4FF3-BCA5-7182BB17AB72Q64699039-E4FA42C9-4A8E-423A-B3FE-85B18D627385Q64708801-414EF856-FDCA-4170-9F7B-489190AB5667Q64708823-01A4CA05-390D-4717-ADD3-9966300D9F65Q64722018-3B670ED9-2036-4AE3-9B0F-DB72BD707BE1Q65349469-5B1E06F8-98EA-4AE8-88E1-ABA72788EBD2Q65360515-36F26C62-4C6E-4A0D-A5AD-5F8425CC64C5Q65362187-25C0436C-99F6-4143-A119-9F28CD2A870BQ65372237-09B6518F-B7D1-48AE-9C23-9203EA109615Q65384401-2F9D9B30-0D27-450D-8971-76CE2FE44ABEQ65388537-80475252-02AC-4A22-AD8E-993547B544D5Q65391291-9DC3CE43-E4F7-4275-A0FD-8212BD7395E2Q65400203-683B2380-6C03-47C2-BF24-581363A64AE4Q65538639-BA0B5878-D177-4A21-9FEE-630ED356C49FQ65543862-79E9534C-9CD6-4DCA-8A78-95081D18908EQ65543866-4BD02EFE-F3D2-4139-B8F8-5834913C41EAQ66030150-FC8D1277-53D3-4FD6-99F3-4F79980038FAQ66039351-3F66AC84-3C6E-433A-BDF2-8F04D5A9C75DQ66039620-5701741F-2FB7-455F-90E4-15A295DCD67A
P921
description
Human disease
@en
Krankheit
@de
مرض يصيب الإنسان
@ar
name
glaucome à angle ouvert primitif
@fr
primary open angle glaucoma
@en
primært openvinkelglaukom
@nn
type
label
glaucome à angle ouvert primitif
@fr
primary open angle glaucoma
@en
primært openvinkelglaukom
@nn
altLabel
chronic simple glaucoma
@en
kronisk simpleksglaukom
@nn
primært glaukom med open framkammervinkel
@nn
prefLabel
glaucome à angle ouvert primitif
@fr
primary open angle glaucoma
@en
primært openvinkelglaukom
@nn
P2293
P1417
topic/primary-open-angle-glaucoma